Previous Study: TRIO 016
Next Study: TRIO-CIRG 011

Studies & Results

TRIO 017

A Phase II, Open-label Multicenter Trial of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer

View FDA Study View EU Study

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at